Abstracts tagged "Cerebrovascular disease"

Abstract Number: 024 • 2023 Pediatric Rheumatology Symposium
Effects of Corticosteroids on Central Nervous System Microvascular Properties Assessed by Neuroimaging
Mark DiFrancesco, Ekemini Ogbu, Catherine Robben, Jennifer Huggins and Hermine Brunner, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Prior research suggests that microvascular (MV) changes might be a biomarker for central nervous system (CNS) involvement of patients with systemic lupus erythematosus (SLE).…
Abstract Number: 1127 • 2018 ACR/ARHP Annual Meeting
Risk of Stroke Among Patients with Gout in Taiwan: A Nationwide Population Study
Ping-Han Tsai and Chang-Fu Kuo, Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: To determine whether the Taiwanese patients with gout have a higher risk of stroke.Methods: Using the National Health Insurance database, we identified a cohort…
Abstract Number: 2169 • 2018 ACR/ARHP Annual Meeting
Temporal Trends in Mortality in Patients Hospitalized for Cerebrovascular Events with Psoriatic Arthritis: Data from the Healthcare Cost and Utilization Project from 2010-2014
Shraddha Jatwani¹, Karan Chugh², Karan Jatwani³, Stuthi Perimbeti⁴, Vivek Modi⁵, Jasleen Kaur⁶ and Rakesh K Sharma⁷, ¹Department of Internal Medicine, Division of Rheumatology, Henry Ford Allegiance Health, Jackson, MI, ²Division of Pulmonary, Critical Care & Sleep, Wayne State University/Detroit Medical Center, Detroit, MI, ³Department of Internal Medicine, Mount Sinai West - St Luke’s Hospital, New York, NY, ⁴Department of Internal Medicine, Mount Sinai West - St Luke’s Hospital,, NEW YORK, NY, ⁵Department of Internal Medicine, Mount Sinai West - St Luke’s Hospital,, New York, NY, ⁶Department of Internal Medicine, Wayne State University/Detroit Medical Center, Detroit, MI, ⁷Department of Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India
Background/Purpose: Cerebrovascular disease risk in increased in patients of Psoriatic arthritis (PsA), as reported in the literature. Epidemiological studies to assesses average annual trends are…
Abstract Number: 2226 • 2018 ACR/ARHP Annual Meeting
Gout and the Risk of Incident Dementia in the Elderly: A Medicare Claims Study
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The pursuit of a link between gout/hyperuricemia and dementia has led to contradictory results. Most observational studies, including population-based studies, showed that hyperuricemia was…
Abstract Number: 2359 • 2017 ACR/ARHP Annual Meeting
Severity of Ischemic and Hemorrhagic Stroke in Patients with Rheumatoid Arthritis Compared with the General Population
Mei-Yun Hsieh¹, Chang-Fu Kuo², Kuang-Hui Yu², Shue-Fen Luo^2,3 and Yen-Fu Chen², ¹Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ²Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ³Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) patients are at higher risk of developing stroke but whether their risks for severe strokes are unknown. Methods: All patients with…
Abstract Number: 2759 • 2017 ACR/ARHP Annual Meeting
The Risk of Ischaemic Stroke in Primary APS Patients: A Prospective Study
Massimo Radin¹, Karen Schreiber², Irene Cecchi³, Dario Roccatello⁴, Maria Jose Cuadrado⁵ and Savino Sciascia⁶, ¹Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ²Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁵St Thomas Hospital, Lupus Research Unit, London, United Kingdom, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: The antiphospholipid syndrome(APS)is an autoimmune condition characterized by thrombosis and/or pregnancy morbidity andpersistent positivityfor antiphospholipid antibodies(aPL). The most common neurological manifestation of APS is…
Abstract Number: 2972 • 2017 ACR/ARHP Annual Meeting
Risk of Myocardial Infarction and Cerebrovascular Accident in Ankylosing Spondylitis: A General Population-Based Study
Anthony So¹, Jonathan Chan², Eric C. Sayre³ and J. Antonio Avina-Zubieta^3,4, ¹University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: There is conflicting data on the risk of myocardial infarction (MI) and cerebrovascular accidents (CVA) in patients with Ankylosing Spondylitis (AS). This study attempts…
Abstract Number: 905 • 2016 ACR/ARHP Annual Meeting
Platelet Activation, As Measured By Plasma Soluble Glycoprotein VI, Is Not Associated with Disease Activity or Ischaemic Events in Giant Cell Arteritis
Richard Conway¹, Anne Madigan², Laura Helbert³, Niamh Redmond⁴, Eimear Dunne⁵, Eamonn S. Molloy⁶, Dermot Kenny⁵ and Geraldine M. McCarthy⁷, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ³Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁴UCD Clinical Research Centre, Dublin, Ireland, ⁵Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ⁶Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin, Ireland, ⁷Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Patients with Giant Cell Arteritis (GCA) have an increased risk of devastating cranial ischaemic complications including vision loss and stroke. The BSR guidelines recommend…
Abstract Number: 1483 • 2016 ACR/ARHP Annual Meeting
Elevated Anti-Cyclic Citrullinated Peptide Antibody Titer Is Associated with Increased Cardiovascular Risk
Sarah A. Fantus¹, Melissa R. Bussey², Rochella A. Ostrowski³, Andrew Heisler¹ and Kyle Carey⁴, ¹Internal Medicine, Loyola University Medical Center, Maywood, IL, ²Division of Allergy, Immunology, and Rheumatology, Loyola University Medical Center, Maywood, IL, ³Rheumatology, Loyola University Medical Center, Maywood, IL, ⁴Clinical Research Office, Loyola University Chicago, Maywood, IL
Background/Purpose: Rheumatoid arthritits (RA) patients have an increased risk of mortality from cardiovascular (CV) disease. Proposed adaptation of CV risk score models in RA patients…
Abstract Number: 1993 • 2016 ACR/ARHP Annual Meeting
The Risk of Stroke in Patients with Rheumatoid Arthritis and the Association with Competing Adverse Events
Yvette Meißner¹, Adrian Richter², Joern Kekow³, Hans Peter Tony⁴, Elke Wilden⁵, Angela Zink^6,7, Joachim Listing² and Anja Strangfeld⁷, ¹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³University of Magdeburg, Clinic of Rheumatology, Magdeburg, Germany, ⁴Rheumatology / Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ⁵Rheumatologist, Köln, Germany, ⁶Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁷Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for infections, hospitalizations and cardiovascular (CV) events. The association of serious adverse events (SAE) with…
Abstract Number: 3092 • 2015 ACR/ARHP Annual Meeting
Deficiency of Adenosine Deaminase Type II – Expanding the Clinical Spectrum
Karyl Barron¹, Amanda Ombrello², Deborah Stone², Patrycja Hoffmann², Ivona Aksentijevich^2,3, Qing Zhou², Anne Jones² and Daniel L. Kastner⁴, ¹NIAID/NIH, Bethesda, MD, ²NHGRI/NIH, Bethesda, MD, ³Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ⁴Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: The deficiency of adenosine deaminase II (DADA2), first described in 2014, is an autosomal recessive disease caused by mutations in CECR1and is characterized by…
Abstract Number: 3159 • 2015 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Is a Risk Factor for Young Stroke: A Population-Based Cohort Study
Elizabeth V Arkema¹, Elisabet Svenungsson², Christopher Sjöwall³ and Julia F Simard^4,5, ¹Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Karolinska Insitutet, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ³Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, ⁴Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ⁵Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Previous studies indicate that individuals with SLE have a high risk of stroke but have not investigated when the highest risk occurs. We aimed…
Abstract Number: 819 • 2015 ACR/ARHP Annual Meeting
Upregulation of Complement C3 and Alpha-2-Macroglobulin in Cerebrospinal Fluid of Neuropsychiatric Systemic Lupus Erythematosus
Tomoyuki Asano¹, Shuzo Sato¹, Hiroko Kobayashi¹, Yoshinobu Kariya², Hiromi Ito², Kyoka Hoshi², Akioh Yoshihara³, Yoshikazu Ugawa³, Minoru Takahashi⁴, Hideharu Sekine⁴, Shunsei Hirohata⁵, Hiroshi Watanabe¹, Hiromasa Ohira¹ and Yasuhiro Hashimoto², ¹Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan, ²Biochemistry, Fukushima Medical University School of Medicine, Fukushima, Japan, ³Neurology, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁴Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁵Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan
Background/Purpose: Various autoantibodies have been identified in cerebrospinal fluids (CSF) of neuropsychiatric systemic lupus erythematosus (NPSLE). They are supposed to form immune complex with complement…
Abstract Number: 1752 • 2015 ACR/ARHP Annual Meeting
Characterization of Epitopes Identified with Cerebral Vasculature Injury
Melissa Butts¹, Jess Edison¹, Christopher Tracy¹, Brian Stout¹, Huazhen Chen² and Chantal Moratz², ¹Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ²Medicine, Uniformed Services University School of Health Sciences, Bethesda, MD
Background/Purpose: There is an association between natural antibodies, such as anti-phospholipid antibodies, and vasculature injury in stroke and in SLE models of systemic ischemic damage. …
Abstract Number: 1972 • 2015 ACR/ARHP Annual Meeting
Cardiovascular and Cerebrovascular Disease and Social Deprivation in Patients with Giant Cell Arteritis
Joanna Robson¹, Amit Kiran², Andrew Hutchings³, Joseph Maskell⁴, Nigel K Arden⁵, Willie Hamilton⁶, Bhaskar Dasgupta^7,8 and Raashid Luqmani⁹, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ³Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, ⁴Faculty of Medicine, University of Southampton, Southampton, United Kingdom, ⁵Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁶Primary Care, University of Exeter, Exeter, United Kingdom, ⁷Southend University Hospital, Southend, United Kingdom, ⁸Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in the UK, with an incidence of 2.2 cases per 10,000 person-years. Cerebrovascular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].